Inovio Pharmaceuticals reports Q1 loss of $30.47M, plans BLA filing for INO-3107 (RRP) in H2 2024 and discusses phase

Inovio Pharmaceuticals reported a Q1 loss of $30.47M, down from $40.65M in the previous year. The company is on track to file a Biologic License Application (BLA) for its first product, INO-3107, treating recurrent respiratory papillomatosis (RRP), in the second half of 2024. INO-3112, a throat cancer treatment, is also progressing, with plans for phase 3 trial designs being discussed.

May 13, 2024
6 Articles